Education
About Us
Working with TipRanks
Follow Us
Gilead Sciences (GILD)
NASDAQ:GILD
GILD Stock Chart & Stats
$124.29
-$0.76(-0.84%)
At close: 4:00 PM EST
$124.29
-$0.76(-0.84%)
Day’s Range― - ―
52-Week Range$88.57 - $128.70
Previous CloseN/A
Volume1.95M
Average Volume (3M)6.92M
Market Cap
$154.20B
Enterprise Value$154.88B
Total Cash (Recent Filing)$7.35B
Total Debt (Recent Filing)$24.94B
Price to Earnings (P/E)19.3
Beta0.32
Next Earnings
Feb 10, 2026EPS Estimate
1.86Next Dividend Ex-DateN/A
Dividend Yield2.54%
Share Statistics
EPS (TTM)2.47
Shares Outstanding1,240,679,600
10 Day Avg. Volume7,415,018
30 Day Avg. Volume6,918,022
Financial Highlights & Ratios
PEG Ratio-2.62
Price to Book (P/B)5.96
Price to Sales (P/S)4.01
P/FCF Ratio11.18
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue5.32
Enterprise Value/Gross Profit6.76
Enterprise Value/Ebitda11.33
Forecast
1Y Price Target
$134.63Price Target Upside8.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
EPS Forecast (FY)8.16
Revenue Forecast (FY)$29.21B
Bulls Say, Bears Say
Bulls Say
HIV Treatment DevelopmentThe Ph3 ARTISTRY-1 trial of bictegravir/lenacapavir in virologically suppressed HIV patients on complex treatment regimens met the non-inferiority primary endpoint.
Market PenetrationPenetration into the market of patients not on Biktarvy provides upside to Gilead Sciences' HIV revenue in future years.
Oncology Franchise GrowthThe Outperform rating is supported by positivity on the oncology franchise as the company's next leg of growth.
Bears Say
Oncology CompetitionOn the oncology side, performance is somewhat lackluster as CAR-T faces increasing competition.
Sample Size ConcernsThe extremely small sample size and limited amount of patient follow-up muddies comparisons to Gilead/Arcellx's program.
Valuation ConcernsFairly valued – GILD shares trade at a P/E multiple of 13.7x 2026E consensus EPS vs. a large-cap BioPharma peer average of 13.5x. Combined with what is seen as comparatively modest growth prospects ex-HIV, shares are considered fairly valued.
Gilead Sciences News
GILD FAQ
What was Gilead Sciences’s price range in the past 12 months?
Gilead Sciences lowest stock price was $88.57 and its highest was $128.70 in the past 12 months.
What is Gilead Sciences’s market cap?
Gilead Sciences’s market cap is $154.20B.
When is Gilead Sciences’s upcoming earnings report date?
Gilead Sciences’s upcoming earnings report date is Feb 10, 2026 which is in 51 days.
How were Gilead Sciences’s earnings last quarter?
Gilead Sciences released its earnings results on Oct 30, 2025. The company reported $2.47 earnings per share for the quarter, beating the consensus estimate of $2.132 by $0.338.
Is Gilead Sciences overvalued?
According to Wall Street analysts Gilead Sciences’s price is currently Undervalued.
Does Gilead Sciences pay dividends?
Gilead Sciences pays a Quarterly dividend of $0.79 which represents an annual dividend yield of 2.54%. See more information on Gilead Sciences dividends here
What is Gilead Sciences’s EPS estimate?
Gilead Sciences’s EPS estimate is 1.86.
How many shares outstanding does Gilead Sciences have?
Gilead Sciences has 1,240,679,600 shares outstanding.
What happened to Gilead Sciences’s price movement after its last earnings report?
Gilead Sciences reported an EPS of $2.47 in its last earnings report, beating expectations of $2.132. Following the earnings report the stock price went up 1.139%.
Which hedge fund is a major shareholder of Gilead Sciences?
Currently, no hedge funds are holding shares in GILD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Gilead Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$134.63 (8.32% Upside)
$134.63 (8.32% Upside)
Blogger Sentiment
Bullish
GILD Sentiment 87%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $625.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.68%
12-Months-Change
Fundamentals
Return on Equity
40.53%
Trailing 12-Months
Asset Growth
7.35%
Trailing 12-Months
Company Description
Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company headquartered in Foster City, California, focused on the discovery, development, and commercialization of innovative medicines in areas of unmet medical need. The company primarily operates in the therapeutic sectors of antiviral, oncology, and inflammation, with a strong emphasis on treatments for HIV/AIDS, liver diseases, and cancer. Gilead's core products include well-known antiviral medications such as Truvada, Biktarvy, and Harvoni, along with a growing portfolio of oncology therapies and other therapeutic agents.
GILD Company Deck
GILD Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant growth in the HIV portfolio and successful launches of new products like Yeztugo, boosting revenue expectations despite challenges in oncology and cell therapy segments. The overall sentiment is positive, driven by strong commercial execution and strategic advancements.View all GILD earnings summariesGILD Revenue Breakdown
68.21% HIV
10.51% Liver Disease
6.26% Veklury
11.44% Oncology
3.09% Other
0.50% Royalty, contract and other revenues
GILD Stock 12 Month Forecast
Average Price Target
$134.63
▲(8.32% Upside)
Technical Analysis
Ownership Overview
0.09% Insiders
29.15% Mutual Funds
18.26% Other Institutional Investors
25.14% Public Companies and Individual Investors